| 000 | 01660 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250513062611.0 | ||
| 264 | 0 | _c19940428 | |
| 008 | 199404s 0 0 eng d | ||
| 022 | _a0277-3732 | ||
| 024 | 7 |
_a10.1097/00000421-199404000-00002 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aConroy, T | |
| 245 | 0 | 0 |
_aAcute antiemetic efficacy and safety of dolasetron mesylate, a 5-HT3 antagonist, in cancer patients treated with cisplatin. European Dolasetron Study Group. _h[electronic resource] |
| 260 |
_bAmerican journal of clinical oncology _cApr 1994 |
||
| 300 |
_a97-102 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aCisplatin _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIndoles _xadverse effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNausea _xchemically induced |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aQuinolizines _xadverse effects |
| 650 | 0 | 4 |
_aSerotonin Antagonists _xtherapeutic use |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVomiting _xchemically induced |
| 700 | 1 | _aCappelaere, P | |
| 700 | 1 | _aFabbro, M | |
| 700 | 1 | _aFauser, A A | |
| 700 | 1 | _aSplinter, T A | |
| 700 | 1 | _aSpielmann, M | |
| 700 | 1 | _aSchneider, M | |
| 700 | 1 | _aChevallier, B | |
| 700 | 1 | _aGoupil, A | |
| 700 | 1 | _aChauvergne, J | |
| 773 | 0 |
_tAmerican journal of clinical oncology _gvol. 17 _gno. 2 _gp. 97-102 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/00000421-199404000-00002 _zAvailable from publisher's website |
| 999 |
_c8140436 _d8140436 |
||